KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest Expenses (2016 - 2023)

Supernus Pharmaceuticals (SUPN) has disclosed Interest Expenses for 13 consecutive years, with $910000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Interest Expenses fell 49.72% to $910000.0 in Q2 2023 year-over-year; TTM through Mar 2024 was $910000.0, a 86.28% decrease, with the full-year FY2023 number at $2.4 million, down 65.84% from a year prior.
  • Interest Expenses was $910000.0 for Q2 2023 at Supernus Pharmaceuticals, down from $1.5 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $6.1 million in Q1 2021 to a low of $910000.0 in Q2 2023.
  • A 5-year average of $4.4 million and a median of $5.7 million in 2019 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 718.69% in 2019, then plummeted 73.14% in 2022.
  • Supernus Pharmaceuticals' Interest Expenses stood at $5.8 million in 2019, then increased by 5.52% to $6.1 million in 2020, then fell by 2.66% to $5.9 million in 2021, then plummeted by 73.14% to $1.6 million in 2022, then plummeted by 42.91% to $910000.0 in 2023.
  • Per Business Quant, the three most recent readings for SUPN's Interest Expenses are $910000.0 (Q2 2023), $1.5 million (Q1 2023), and $1.6 million (Q4 2022).